---
WhyPharma-Grade L-Arginine Demands Rigorous Standards?
The 2024 USP-NF revisions now require:
- Stricter impurity profiling (≤0.1% individual unknown)
- Enhanced endotoxin controls (<0.05EU/mg for injectables)
- Full elemental analysis (13 heavy metalstested)
As an FDA-registered manufacturer with 10+years of cGMP compliance, we meet these challenges through:
---
OurPharmaceutical Quality Edge
1.Uncompromising Raw Material Control
- Dual-sourced fermentation substrates withDNA traceability
- USP<85> compliant microbial limitstesting
2.Advanced Purification Process
- Multi-stage crystallization for ≥99.8% purity
- Nanofiltration achieving endotoxin levels<0.03 EU/mg
- ICH Q3D-compliant metal control
3.Comprehensive Documentation
- Type II DMF available (FDA : xxxxx)
- 72-month stability data (25°C/60%RH)
- Batch-specific:
-HPLC-ELSD chromatograms
-Residual solvent reports
-Counter-ion analysis
---
CriticalApplications Supported
1. Injectable Formulations
-IV solutions requiring pyrogen-free status
-Pre-filled syringes needing pH stability
2. Cardiovascular Drugs
-NO synthase-dependent formulations
-Critical care medications
3. Advanced Delivery Systems
-Liposomal encapsulation grades
-PEGylated derivatives
---
Technical& Regulatory Support
✔Pre-audit documentation review
✔Custom particle engineering(10-150μm)
✔Excipient compatibility studies
Start Your Qualification Process: